DE69842021D1 - Aminozucker, Chondroitin und S-Adenosylmethionin enthaltende Zusammensetzungen - Google Patents

Aminozucker, Chondroitin und S-Adenosylmethionin enthaltende Zusammensetzungen

Info

Publication number: DE69842021D1
Authority: DE; Germany
Prior art keywords: composition; salts; chondroitin; sulfate; connective tissue
Prior art date: 1997-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69842021T

Other languages

English (en)

Inventor

Robert W Henderson

Todd Henderson

Tarek Hammad

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nutramax Laboratories Inc

Original Assignee

Nutramax Laboratories Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-28

Filing date

1998-04-17

Publication date

2011-01-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25296238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69842021(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-17 Application filed by Nutramax Laboratories Inc filed Critical Nutramax Laboratories Inc

2011-01-05 Application granted granted Critical

2011-01-05 Publication of DE69842021D1 publication Critical patent/DE69842021D1/de

2018-04-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title abstract 8
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title abstract 3
229960001570 ademetionine Drugs 0.000 title abstract 3
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 title abstract 3
229920002567 Chondroitin Polymers 0.000 title abstract 2
150000002337 glycosamines Chemical class 0.000 title abstract 2
210000002808 connective tissue Anatomy 0.000 abstract 3
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract 3
229920002683 Glycosaminoglycan Polymers 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
239000012634 fragment Substances 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract 1
RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 abstract 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 abstract 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
REEBJQTUIJTGAL-UHFFFAOYSA-N 3-pyridin-1-ium-1-ylpropane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCC[N+]1=CC=CC=C1 REEBJQTUIJTGAL-UHFFFAOYSA-N 0.000 abstract 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 abstract 1
229920002971 Heparan sulfate Polymers 0.000 abstract 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
229920000288 Keratan sulfate Polymers 0.000 abstract 1
102000011782 Keratins Human genes 0.000 abstract 1
108010076876 Keratins Proteins 0.000 abstract 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 abstract 1
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 abstract 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 abstract 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 abstract 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
229960003237 betaine Drugs 0.000 abstract 1
239000011575 calcium Substances 0.000 abstract 1
229910052791 calcium Inorganic materials 0.000 abstract 1
FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 1
229940019765 dermatin Drugs 0.000 abstract 1
108700003601 dimethylglycine Proteins 0.000 abstract 1
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 abstract 1
229960000304 folic acid Drugs 0.000 abstract 1
235000019152 folic acid Nutrition 0.000 abstract 1
239000011724 folic acid Substances 0.000 abstract 1
229960002442 glucosamine Drugs 0.000 abstract 1
150000002301 glucosamine derivatives Chemical class 0.000 abstract 1
229960001911 glucosamine hydrochloride Drugs 0.000 abstract 1
229920002674 hyaluronan Polymers 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 abstract 1
229910052748 manganese Inorganic materials 0.000 abstract 1
239000011572 manganese Substances 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229950006780 n-acetylglucosamine Drugs 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1
229940045999 vitamin b 12 Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

DE69842021T 1997-04-28 1998-04-17 Aminozucker, Chondroitin und S-Adenosylmethionin enthaltende Zusammensetzungen Expired - Lifetime DE69842021D1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/845,852 US6255295B1 (en)	1996-12-23	1997-04-28	Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue

Publications (1)

Publication Number	Publication Date
DE69842021D1 true DE69842021D1 (de)	2011-01-05

Family

ID=25296238

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE69842021T Expired - Lifetime DE69842021D1 (de)	1997-04-28	1998-04-17	Aminozucker, Chondroitin und S-Adenosylmethionin enthaltende Zusammensetzungen
DE69840668T Expired - Lifetime DE69840668D1 (de)	1997-04-28	1998-04-17	Aminozucker, glycosaminoglycan oder glycosaminoglycan-ähnliche verbindungen und s-adenosylmethionin

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE69840668T Expired - Lifetime DE69840668D1 (de)	1997-04-28	1998-04-17	Aminozucker, glycosaminoglycan oder glycosaminoglycan-ähnliche verbindungen und s-adenosylmethionin

Country Status (13)

Country	Link
US (1)	US6255295B1 (de)
EP (2)	EP1849471B1 (de)
AT (2)	ATE489099T1 (de)
AU (1)	AU747595B2 (de)
CA (3)	CA2539919A1 (de)
CY (1)	CY1109064T1 (de)
DE (2)	DE69842021D1 (de)
DK (1)	DK0979090T3 (de)
ES (2)	ES2324565T3 (de)
HK (1)	HK1114774A1 (de)
NZ (1)	NZ500025A (de)
PT (1)	PT979090E (de)
WO (1)	WO1998048816A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010000472A1 (en) *	1998-02-27	2001-04-26	Nutramax Laboratories, Inc.	L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
CA2333752A1 (en) *	1998-06-04	1999-12-09	Tarek Hammad	Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
EP1762247A1 (de) *	1998-06-05	2007-03-14	Nutramax Laboratories, Inc.	Verwendung von Anabolika, antikatabolischen Mitteln, Antioxidationsmittel und Analgetika zum Schutz sowie zur Behandlung und Wiederherstellung von Bindegewebe bei Menschen und Tieren
ES2278447T3 (es) *	1998-06-05	2007-08-01	Nutramax Laboratories, Inc.	El uso de agentes anabolicos, agentes anticatabolicos, agentes antioxidantes y analgesicos para la proteccion, tratamiento y reparacion de tejidos conectivos en humanos y animales.
US6656925B2 (en) *	1998-09-09	2003-12-02	Advanced Medical Instruments	Composition and method of treating arthritis
US20020018787A1 (en)	1999-05-21	2002-02-14	Roger V. Kendall	Methods and compositions for modulating immune response and for the treatment of inflammatory disease
AU727355B3 (en) *	1999-07-21	2000-12-14	Bomac Laboratories Limited	Compositions addressing inflammation and/or degenerative disorders
US6524609B1 (en) *	1999-08-18	2003-02-25	Nutri-Vet, Llc	Treating arthritis in animals with dietary supplements
AU7863400A (en) *	1999-10-08	2001-04-23	Pharmnseas, Inc.	Nutraceutical products containing same and dietary supplements and method of manufacture and use thereof
US20050282774A1 (en) *	2000-10-31	2005-12-22	Eek Bjorn C	Method and pharmaceutical to treat spinal discs
CA2435637A1 (en)	2001-01-23	2002-08-01	Massachusetts Institute Of Technology	Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
US6689391B2 (en)	2001-03-30	2004-02-10	Council Of Scientific & Industrial Research	Natural non-polar fluorescent dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses
US6916492B2 (en)	2001-03-30	2005-07-12	Council Of Scientific & Industrial Research	Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
BRPI0101486B1 (pt) *	2001-04-17	2017-09-19	Cristália Produtos Químicos Farmacêuticos Ltda.	Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
US20030134825A1 (en) *	2002-01-03	2003-07-17	Robert Bahoshy	Food product supplemented with proteoglycan precursors
US20030138543A1 (en) *	2002-01-03	2003-07-24	Bradley T. Baumann	Food product supplemented with proteoglycan precursors
US7387796B2 (en) *	2002-01-30	2008-06-17	Hebert Rolland F	Stable compositions of S-adenosyl-l-methionine with dextran
CA2476126A1 (en) *	2002-02-15	2003-08-21	Ocean Nutrition Canada Limited	Shark cartilage extracts and use thereof for immunomodulation
US20030170374A1 (en) *	2002-03-05	2003-09-11	Robert Bahoshy	Condiments including nutritional supplements
CA2482746A1 (en) *	2002-04-19	2003-11-27	Astion Development A/S	Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
US7485629B2 (en) *	2002-10-16	2009-02-03	Arthrodynamic Technologies, Animal Health Division, Inc.	Composition and method for treatment of joint damage
US7504387B2 (en) *	2002-10-16	2009-03-17	Arthrodynamic Technologies, Animal Health Division, Inc.	Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
DE10260958A1 (de) *	2002-12-20	2004-07-08	Sustech Gmbh & Co. Kg	Kompositmaterialien aus Calciumverbindungen und Glucuronsäure- und/oder Iduronsäurehaltigen Polysacchariden
US6946551B2 (en) *	2003-03-12	2005-09-20	New Life Resources, Llc	Preparation of hyaluronic acid from eggshell membrane
US20080063677A1 (en) *	2004-03-10	2008-03-13	New Life Resources, Llc	Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20040180025A1 (en) *	2003-03-12	2004-09-16	New Life Resources, Llc	Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20050176807A1 (en) *	2004-02-09	2005-08-11	Friesen Kim G.	Composition and method for use in cartilage affecting conditions
US8377904B2 (en) *	2004-02-09	2013-02-19	Hill's Pet Nutrition, Inc.	Composition and method for use in cartilage affecting conditions
US20050176674A1 (en) *	2004-02-09	2005-08-11	Friesen Kim G.	Composition and method for use in cartilage affecting conditions
US8580315B2 (en) *	2004-03-10	2013-11-12	Esm Technologies, Llc	Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
WO2007014155A2 (en) *	2005-07-22	2007-02-01	Trf Pharma, Inc.	Method for treating sickle cell disease and sickle cell disease sequelae
US8598144B1 (en)	2005-11-10	2013-12-03	Reyn Pharma, Llc	Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en)	2005-11-10	2016-11-15	Reyn Pharma, Llc	Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
AU2007240993B2 (en) *	2006-04-03	2013-08-01	Ceva Animal Health Pty Ltd	Stabilized pentosan polysulfate (PPS) formulations and methods of analyzing them
JP5175481B2 (ja) *	2006-10-23	2013-04-03	エーザイフード・ケミカル株式会社	軟骨再生促進剤
EP2162153B1 (de) *	2007-06-06	2016-03-30	Novus International Inc.	Nahrungsergänzungen zur förderung von wachstum, reparatur und erhaltung von knochen und gelenken
US7947662B2 (en) *	2008-02-20	2011-05-24	Gnosis S.P.A.	Folates, compositions and uses thereof
US8163716B1 (en)	2008-06-30	2012-04-24	Smith James D	Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en)	2008-07-02	2012-05-15	Smith James D	Method of administering hyaluronan formulation for the amelioration of osteopenia
CA2773776C (en) *	2009-09-23	2018-09-25	Glenpharma Ab	Compositions and methods for inducing or enhancing connective tissue repair
FR2996137B1 (fr) *	2012-10-01	2017-10-27	Sp2L	Composition comprenant de l'acide hyaluronique, du manganese et de la vitamine c
WO2020089236A1 (en)	2018-11-02	2020-05-07	Unilever Plc	Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
IT202100030935A1 (it)	2021-12-09	2023-06-09	Fidia Farm Spa	Compresse comprendenti condroitin solfato, glucosamina cloridrato e vitamina c per il trattamento di danni cartilaginei, tendinei, ossei

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3232836A (en)	1959-08-24	1966-02-01	Pfizer & Co C	Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US3371012A (en)	1964-08-07	1968-02-27	Seikagaku Kogyo Co Ltd	Preservative for eye graft material
DE1792346C3 (de)	1968-08-22	1980-10-23	Rotta Research Laboratorium S.P.A., San Fruttuoso Di Monza, Mailand (Italien)	Pharmazeutisches Präparat für die Behandlung von degenerativen Gelenkerkrankungen
IT1044707B (it)	1968-10-26	1980-04-21	Rotta Research Lab	Procedimento per la preparazione di sali di glucosanina e preparati farmaceutici comprendenti detti sali di glucosamina come agenti attivi
JPS5027884A (de)	1973-07-12	1975-03-22
US4006224A (en)	1975-09-29	1977-02-01	Lescarden Ltd.	Method and agent for treating inflammatory disorders of the gastrointestinal tract
US4378224A (en)	1980-09-19	1983-03-29	Nimni Marcel E	Coating for bioprosthetic device and method of making same
US5180715A (en)	1980-11-17	1993-01-19	The Regents Of The University Of California	Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US4486416A (en)	1981-03-02	1984-12-04	Soll David B	Protection of human and animal cells subject to exposure to trauma
IT1137640B (it)	1981-08-24	1986-09-10	Bioresearch Srl	Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
IT1137892B (it)	1981-08-24	1986-09-10	Bioresearch Srl	Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
US4473551A (en)	1982-08-23	1984-09-25	Faxon Pharmaceuticals, Inc.	Anti-inflammatory composition
FR2543145B1 (fr)	1983-03-24	1986-10-17	Sanofi Sa	Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante
IT1173990B (it)	1984-05-16	1987-06-24	Bioresearch Spa	Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale
IT1173992B (it)	1984-05-16	1987-06-24	Bioresearch Spa	Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale
US4711780A (en)	1984-06-11	1987-12-08	Fahim Mostafa S	Composition and process for promoting epithelial regeneration
DE3422407A1 (de)	1984-06-16	1986-03-06	B. Braun Melsungen Ag, 3508 Melsungen	Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma
DE3432661A1 (de)	1984-09-05	1986-03-06	Albert Prof. Dr. 6907 Nußloch Landsberger	Carcinom-therapeutikum
US4647453A (en)	1984-10-18	1987-03-03	Peritain, Ltd.	Treatment for tissue degenerative inflammatory disease
FR2572731B1 (fr)	1984-11-07	1987-03-06	Sanofi Sa	Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale
SE8501723L (sv)	1985-04-09	1986-10-10	Pharmacia Ab	Preparation att anvendas vid behandling av ledinflammation
US4707354A (en)	1985-06-17	1987-11-17	Alpen Tau, Inc.	Mature skin treatment and protectant compositions and methods of using same
US4772591A (en)	1985-09-25	1988-09-20	Peritain, Ltd.	Method for accelerated wound healing
DE3602670A1 (de)	1986-01-29	1987-07-30	Speck Ulrich	Verwendung von n-acetylglucosamin zur therapie degenerativer gelenkprozesse und verwandter erkrankungen
US4966890A (en)	1986-04-04	1990-10-30	Angiogenics, Ltd.	Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4983580A (en)	1986-04-04	1991-01-08	Allergan, Inc.	Methods and materials for use in corneal wound healing
US4820693A (en)	1986-05-22	1989-04-11	Angiogenics, Ltd.	Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US5385938B1 (en)	1986-12-23	1997-07-15	Tristrata Inc	Method of using glycolic acid for treating wrinkles
US5091171B2 (en)	1986-12-23	1997-07-15	Tristrata Inc	Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5668116A (en)	1987-03-19	1997-09-16	Anthropharm Pty. Limited	Anti-inflammatory compounds and compositions
ATE129254T1 (de) *	1987-03-19	1995-11-15	Arthropharm Pty Ltd	Antientzündungsmittel und zusammensetzungen.
US5263984A (en)	1987-07-20	1993-11-23	Regen Biologics, Inc.	Prosthetic ligaments
FR2609397B1 (fr)	1988-02-23	1991-12-13	Serobiologiques Lab Sa	Utilisation d'une substance ou composition de nature glucidique comme principe actif d'une composition dermatologique et/ou cosmetologique et/ou pharmaceutique et/ou stimulante cellulaire, et composition contenant une telle substance ou composition de nature glucidique
US5510418A (en)	1988-11-21	1996-04-23	Collagen Corporation	Glycosaminoglycan-synthetic polymer conjugates
GB8900812D0 (en)	1989-01-14	1989-03-08	Univ Manchester	Pharmaceutical method and compositions
FR2649982B1 (fr)	1989-07-20	1991-09-27	Inst Nat Sante Rech Med	Membrane biologique artificielle
DE3942081A1 (de)	1989-12-20	1991-06-27	Behringwerke Ag	Mittel zur verbesserung der wiederfindung von annexinen
US5141928B1 (en)	1989-12-20	1995-11-14	Brujo Inc	Ophthalmic medication
US5514667A (en)	1990-11-05	1996-05-07	Arthropharm Pty. Limited	Method for topical treatment of herpes infections
AU1052492A (en)	1991-01-31	1992-08-06	Farmitalia Carlo Erba S.R.L.	Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
IT1260137B (it)	1992-04-17	1996-03-28	Alfa Wassermann Spa	Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
ATE173627T1 (de)	1992-09-04	1998-12-15	Fuji Chem Ind Co Ltd	Medizinische zusammensetzung
IT1264101B1 (it)	1993-03-29	1996-09-10	Alfa Wassermann Spa	Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
IT1264102B1 (it)	1993-03-29	1996-09-10	Alfa Wassermann Spa	Processo per la sintesi di glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonico sostituito con radicali
US5364845C1 (en) *	1993-03-31	2002-09-10	Nutramax Lab Inc	Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
US5691325A (en)	1994-01-14	1997-11-25	Sandyk; Reuven	Method for ameliorating age-related disease conditions
US5597575A (en)	1994-06-06	1997-01-28	Breitbarth; Richard	Composition for stimulating and inducing hair growth
US5639787A (en)	1995-02-28	1997-06-17	The Center For The Improvement Of Human Functioning Int'l, Inc.	Therapeutic method for the treatment of cancer
WO1996033703A2 (en) *	1995-04-25	1996-10-31	Oridigm Corporation	S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5643892A (en)	1995-06-07	1997-07-01	Baker Norton Pharmaceuticals, Inc.	Method of treating chronic progressive vascular diseases
AU5928396A (en)	1995-06-07	1996-12-30	Monsanto Company	Process for preparing substituted polyazamacrocycles
GB2317109B (en) *	1996-08-28	2000-06-21	Farmsense	A therapeutic composition for the treatment and repair of connective tissue in mammals

1997
- 1997-04-28 US US08/845,852 patent/US6255295B1/en not_active Expired - Lifetime
1998
- 1998-04-17 AT AT07075664T patent/ATE489099T1/de not_active IP Right Cessation
- 1998-04-17 DE DE69842021T patent/DE69842021D1/de not_active Expired - Lifetime
- 1998-04-17 AT AT98915591T patent/ATE425757T1/de active
- 1998-04-17 NZ NZ500025A patent/NZ500025A/en not_active IP Right Cessation
- 1998-04-17 DK DK98915591T patent/DK0979090T3/da active
- 1998-04-17 CA CA002539919A patent/CA2539919A1/en not_active Abandoned
- 1998-04-17 EP EP07075664A patent/EP1849471B1/de not_active Expired - Lifetime
- 1998-04-17 ES ES98915591T patent/ES2324565T3/es not_active Expired - Lifetime
- 1998-04-17 ES ES07075664T patent/ES2357255T3/es not_active Expired - Lifetime
- 1998-04-17 EP EP98915591A patent/EP0979090B1/de not_active Expired - Lifetime
- 1998-04-17 CA CA002286552A patent/CA2286552C/en not_active Expired - Fee Related
- 1998-04-17 WO PCT/US1998/007561 patent/WO1998048816A1/en active IP Right Grant
- 1998-04-17 CA CA002539696A patent/CA2539696A1/en active Pending
- 1998-04-17 DE DE69840668T patent/DE69840668D1/de not_active Expired - Lifetime
- 1998-04-17 PT PT98915591T patent/PT979090E/pt unknown
- 1998-04-17 AU AU69733/98A patent/AU747595B2/en not_active Expired
2008
- 2008-04-30 HK HK08104826.4A patent/HK1114774A1/xx not_active IP Right Cessation
2009
- 2009-05-13 CY CY20091100511T patent/CY1109064T1/el unknown

Also Published As

Publication number	Publication date
CA2286552A1 (en)	1998-11-05
ES2357255T3 (es)	2011-04-20
WO1998048816A1 (en)	1998-11-05
AU747595B2 (en)	2002-05-16
NZ500025A (en)	2002-03-01
EP1849471A1 (de)	2007-10-31
EP0979090B1 (de)	2009-03-18
DE69840668D1 (de)	2009-04-30
ATE489099T1 (de)	2010-12-15
CY1109064T1 (el)	2014-07-02
HK1114774A1 (en)	2008-11-14
CA2539919A1 (en)	1998-11-05
CA2286552C (en)	2007-10-30
CA2539696A1 (en)	1998-11-05
EP1849471B1 (de)	2010-11-24
AU6973398A (en)	1998-11-24
EP0979090A4 (de)	2000-10-18
PT979090E (pt)	2009-05-04
EP0979090A1 (de)	2000-02-16
ES2324565T3 (es)	2009-08-10
DK0979090T3 (da)	2009-06-08
ATE425757T1 (de)	2009-04-15
US6255295B1 (en)	2001-07-03

Publication	Publication Date	Title
DE69842021D1 (de)	2011-01-05	Aminozucker, Chondroitin und S-Adenosylmethionin enthaltende Zusammensetzungen
CA2159591A1 (en)	1994-10-13	Aminosugar and Glycosaminoglycan Composition for the Treatment and Repair of Connective Tissue
ES2374157T3 (es)	2012-02-14	Tratamiento para la sinovitis traumática y el cartílago articular dañado.
BR0009651A (pt)	2002-01-08	Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
BR9811818A (pt)	2000-08-15	Uso de um composto, composto, e, composição farmacêutica
KR940005281A (ko)	1994-03-21	항류마티스성 조성물
BG103430A (en)	2000-07-31	FACTOR Xa INHIBITING HETEROCYCLIC DERIVATIVES
IT1288290B1 (it)	1998-09-11	Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
HK1095139A1 (en)	2007-04-27	Azabicyclic heterocycles as cannabinoid receptor modulators
BR9401920A (pt)	1994-11-29	Sal de sódio de uma heparina despolimerizada, processo para a preparação de uma fração de heparina processo para a preparação de uma heparina de baixo peso molecular, e, composição farmacêutica
EA200000594A1 (ru)	2001-04-23	Новые макролиды
AU758575C (en)	2003-11-20	Compounds having glucuronic acid derivative and glucosamine derivative in structure thereof, method for producing the compounds, and uses of the compounds
PT979244E (pt)	2005-06-30	Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
BR0010380A (pt)	2002-03-26	Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos
EP1070503B8 (de)	2005-09-14	Zusammensetzungen enthaltend Heparin mit niedrigem Molekülargewicht
BR9809951A (pt)	2000-08-01	Método para tratamento da obesidade
NZ577602A (en)	2012-10-26	A composition for treatment of connective tissues
BR9809492A (pt)	2000-06-20	Composição farmacêutica aquosa injetável, e, processo para a preparação da mesma
BR0108728A (pt)	2003-12-30	Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
BR9812577A (pt)	2000-10-17	Composto, processo para preparar o mesmo, composição farmacêutica, e, processo para tratar infecções bacterianas
DK1083929T3 (da)	2007-06-11	Anvendelse af anabolske stoffer
JP2002516866A5 (de)	2006-01-05
AU3658793A (en)	1993-09-03	Bimodal molecular weight hyaluronate formulations and methods for using same
BR0010381A (pt)	2002-02-05	Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
CL2004000765A1 (es)	2005-03-04	Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.